nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—NR5A1—ovarian cancer	0.535	1	CbGaD
Cladribine—ABCG2—Topotecan—ovarian cancer	0.0476	0.387	CbGbCtD
Cladribine—ABCG2—Paclitaxel—ovarian cancer	0.0236	0.191	CbGbCtD
Cladribine—ABCG2—Carboplatin—ovarian cancer	0.0222	0.18	CbGbCtD
Cladribine—ABCG2—Docetaxel—ovarian cancer	0.017	0.138	CbGbCtD
Cladribine—ABCG2—Doxorubicin—ovarian cancer	0.0127	0.103	CbGbCtD
Cladribine—NR5A1—corpus luteum—ovarian cancer	0.0115	0.125	CbGeAlD
Cladribine—NR5A1—ovarian follicle—ovarian cancer	0.00897	0.0978	CbGeAlD
Cladribine—POLE4—embryo—ovarian cancer	0.00258	0.0281	CbGeAlD
Cladribine—POLE2—embryo—ovarian cancer	0.00225	0.0246	CbGeAlD
Cladribine—POLE2—endometrium—ovarian cancer	0.00165	0.018	CbGeAlD
Cladribine—POLE4—female reproductive system—ovarian cancer	0.00156	0.017	CbGeAlD
Cladribine—RRM2B—myometrium—ovarian cancer	0.00138	0.015	CbGeAlD
Cladribine—POLE3—myometrium—ovarian cancer	0.0013	0.0142	CbGeAlD
Cladribine—POLE2—bone marrow—ovarian cancer	0.00129	0.0141	CbGeAlD
Cladribine—POLE3—embryo—ovarian cancer	0.00125	0.0136	CbGeAlD
Cladribine—POLE2—female gonad—ovarian cancer	0.00124	0.0136	CbGeAlD
Cladribine—POLE2—vagina—ovarian cancer	0.00124	0.0135	CbGeAlD
Cladribine—POLE2—testis—ovarian cancer	0.0011	0.012	CbGeAlD
Cladribine—RRM2B—uterine cervix—ovarian cancer	0.00107	0.0117	CbGeAlD
Cladribine—RRM2B—decidua—ovarian cancer	0.00102	0.0111	CbGeAlD
Cladribine—POLE3—uterine cervix—ovarian cancer	0.00101	0.011	CbGeAlD
Cladribine—Floxuridine—TYMS—ovarian cancer	0.00101	0.557	CrCbGaD
Cladribine—POLE—myometrium—ovarian cancer	0.000993	0.0108	CbGeAlD
Cladribine—RRM2B—endometrium—ovarian cancer	0.000969	0.0106	CbGeAlD
Cladribine—POLE3—decidua—ovarian cancer	0.000965	0.0105	CbGeAlD
Cladribine—PNP—uterus—ovarian cancer	0.000962	0.0105	CbGeAlD
Cladribine—POLE—embryo—ovarian cancer	0.000955	0.0104	CbGeAlD
Cladribine—POLE3—endometrium—ovarian cancer	0.000916	0.00998	CbGeAlD
Cladribine—PNP—female reproductive system—ovarian cancer	0.000864	0.00942	CbGeAlD
Cladribine—POLA1—myometrium—ovarian cancer	0.000855	0.00933	CbGeAlD
Cladribine—POLE3—gonad—ovarian cancer	0.000849	0.00926	CbGeAlD
Cladribine—NR5A1—gonad—ovarian cancer	0.000823	0.00897	CbGeAlD
Cladribine—RRM2—myometrium—ovarian cancer	0.000817	0.00891	CbGeAlD
Cladribine—PNP—bone marrow—ovarian cancer	0.000816	0.0089	CbGeAlD
Cladribine—RRM2B—female reproductive system—ovarian cancer	0.000802	0.00875	CbGeAlD
Cladribine—POLE2—lymph node—ovarian cancer	0.0008	0.00872	CbGeAlD
Cladribine—Trifluridine—TYMS—ovarian cancer	0.000799	0.443	CrCbGaD
Cladribine—PNP—female gonad—ovarian cancer	0.000787	0.00857	CbGeAlD
Cladribine—RRM2—embryo—ovarian cancer	0.000786	0.00857	CbGeAlD
Cladribine—POLE—uterine cervix—ovarian cancer	0.000772	0.00842	CbGeAlD
Cladribine—POLE3—female reproductive system—ovarian cancer	0.000759	0.00827	CbGeAlD
Cladribine—RRM2B—bone marrow—ovarian cancer	0.000758	0.00826	CbGeAlD
Cladribine—POLE—decidua—ovarian cancer	0.000736	0.00802	CbGeAlD
Cladribine—NR5A1—female reproductive system—ovarian cancer	0.000735	0.00801	CbGeAlD
Cladribine—RRM2B—female gonad—ovarian cancer	0.00073	0.00796	CbGeAlD
Cladribine—RRM2B—vagina—ovarian cancer	0.000726	0.00791	CbGeAlD
Cladribine—POLE3—bone marrow—ovarian cancer	0.000716	0.00781	CbGeAlD
Cladribine—POLE—endometrium—ovarian cancer	0.000699	0.00762	CbGeAlD
Cladribine—POLE3—female gonad—ovarian cancer	0.00069	0.00752	CbGeAlD
Cladribine—POLE3—vagina—ovarian cancer	0.000686	0.00748	CbGeAlD
Cladribine—RRM1—myometrium—ovarian cancer	0.000679	0.0074	CbGeAlD
Cladribine—SLC28A3—bone marrow—ovarian cancer	0.00067	0.00731	CbGeAlD
Cladribine—NR5A1—female gonad—ovarian cancer	0.000669	0.00729	CbGeAlD
Cladribine—POLA1—uterine cervix—ovarian cancer	0.000666	0.00726	CbGeAlD
Cladribine—POLE—gonad—ovarian cancer	0.000648	0.00706	CbGeAlD
Cladribine—RRM2B—testis—ovarian cancer	0.000648	0.00706	CbGeAlD
Cladribine—SLC28A3—female gonad—ovarian cancer	0.000646	0.00704	CbGeAlD
Cladribine—RRM2—uterine cervix—ovarian cancer	0.000636	0.00693	CbGeAlD
Cladribine—POLA1—decidua—ovarian cancer	0.000634	0.00691	CbGeAlD
Cladribine—POLE3—testis—ovarian cancer	0.000612	0.00667	CbGeAlD
Cladribine—RRM2—decidua—ovarian cancer	0.000606	0.00661	CbGeAlD
Cladribine—POLA1—endometrium—ovarian cancer	0.000602	0.00656	CbGeAlD
Cladribine—NR5A1—testis—ovarian cancer	0.000593	0.00647	CbGeAlD
Cladribine—POLE—female reproductive system—ovarian cancer	0.000579	0.00631	CbGeAlD
Cladribine—RRM2—endometrium—ovarian cancer	0.000575	0.00627	CbGeAlD
Cladribine—PNP—Paclitaxel—Docetaxel—ovarian cancer	0.00057	0.188	CbGdCrCtD
Cladribine—POLE—bone marrow—ovarian cancer	0.000546	0.00596	CbGeAlD
Cladribine—RRM2—gonad—ovarian cancer	0.000534	0.00582	CbGeAlD
Cladribine—RRM2—uterus—ovarian cancer	0.00053	0.00578	CbGeAlD
Cladribine—RRM1—uterine cervix—ovarian cancer	0.000528	0.00576	CbGeAlD
Cladribine—DCK—myometrium—ovarian cancer	0.000527	0.00575	CbGeAlD
Cladribine—POLE—female gonad—ovarian cancer	0.000527	0.00574	CbGeAlD
Cladribine—POLE—vagina—ovarian cancer	0.000523	0.00571	CbGeAlD
Cladribine—DCK—embryo—ovarian cancer	0.000507	0.00553	CbGeAlD
Cladribine—RRM1—decidua—ovarian cancer	0.000503	0.00549	CbGeAlD
Cladribine—RRM1—endometrium—ovarian cancer	0.000478	0.00521	CbGeAlD
Cladribine—RRM2—female reproductive system—ovarian cancer	0.000477	0.00519	CbGeAlD
Cladribine—POLA1—bone marrow—ovarian cancer	0.000471	0.00513	CbGeAlD
Cladribine—RRM2B—lymph node—ovarian cancer	0.000469	0.00512	CbGeAlD
Cladribine—POLE—testis—ovarian cancer	0.000467	0.00509	CbGeAlD
Cladribine—POLA1—female gonad—ovarian cancer	0.000454	0.00495	CbGeAlD
Cladribine—POLA1—vagina—ovarian cancer	0.000451	0.00492	CbGeAlD
Cladribine—RRM2—bone marrow—ovarian cancer	0.00045	0.0049	CbGeAlD
Cladribine—POLA1—Vinblastine—Vinorelbine—ovarian cancer	0.000446	0.147	CbGdCrCtD
Cladribine—POLE3—lymph node—ovarian cancer	0.000444	0.00484	CbGeAlD
Cladribine—RRM1—gonad—ovarian cancer	0.000443	0.00483	CbGeAlD
Cladribine—RRM1—uterus—ovarian cancer	0.00044	0.0048	CbGeAlD
Cladribine—RRM2—female gonad—ovarian cancer	0.000434	0.00473	CbGeAlD
Cladribine—RRM2—vagina—ovarian cancer	0.000431	0.0047	CbGeAlD
Cladribine—DCK—uterine cervix—ovarian cancer	0.00041	0.00447	CbGeAlD
Cladribine—POLA1—testis—ovarian cancer	0.000403	0.00439	CbGeAlD
Cladribine—RRM1—female reproductive system—ovarian cancer	0.000396	0.00432	CbGeAlD
Cladribine—DCK—decidua—ovarian cancer	0.000391	0.00426	CbGeAlD
Cladribine—RRM2—testis—ovarian cancer	0.000385	0.00419	CbGeAlD
Cladribine—RRM1—bone marrow—ovarian cancer	0.000374	0.00407	CbGeAlD
Cladribine—DCK—endometrium—ovarian cancer	0.000371	0.00405	CbGeAlD
Cladribine—RRM1—female gonad—ovarian cancer	0.00036	0.00393	CbGeAlD
Cladribine—RRM1—vagina—ovarian cancer	0.000358	0.0039	CbGeAlD
Cladribine—DCK—gonad—ovarian cancer	0.000344	0.00375	CbGeAlD
Cladribine—DCK—uterus—ovarian cancer	0.000342	0.00373	CbGeAlD
Cladribine—POLE—lymph node—ovarian cancer	0.000339	0.00369	CbGeAlD
Cladribine—RRM1—testis—ovarian cancer	0.00032	0.00348	CbGeAlD
Cladribine—DCK—female reproductive system—ovarian cancer	0.000308	0.00335	CbGeAlD
Cladribine—ABCG2—myometrium—ovarian cancer	0.000294	0.00321	CbGeAlD
Cladribine—POLA1—lymph node—ovarian cancer	0.000292	0.00318	CbGeAlD
Cladribine—DCK—bone marrow—ovarian cancer	0.00029	0.00316	CbGeAlD
Cladribine—DCK—female gonad—ovarian cancer	0.00028	0.00305	CbGeAlD
Cladribine—RRM2—lymph node—ovarian cancer	0.000279	0.00304	CbGeAlD
Cladribine—DCK—vagina—ovarian cancer	0.000278	0.00303	CbGeAlD
Cladribine—DCK—testis—ovarian cancer	0.000248	0.00271	CbGeAlD
Cladribine—POLE2—Idarubicin—Epirubicin—ovarian cancer	0.000247	0.0817	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—ovarian cancer	0.000247	0.0817	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—ovarian cancer	0.000247	0.0817	CbGdCrCtD
Cladribine—SLC22A1—vagina—ovarian cancer	0.000237	0.00259	CbGeAlD
Cladribine—RRM1—lymph node—ovarian cancer	0.000232	0.00252	CbGeAlD
Cladribine—ABCG2—uterine cervix—ovarian cancer	0.000229	0.0025	CbGeAlD
Cladribine—POLE2—Epirubicin—Doxorubicin—ovarian cancer	0.000229	0.0756	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—ovarian cancer	0.000229	0.0756	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—ovarian cancer	0.000229	0.0756	CbGdCrCtD
Cladribine—ABCG2—decidua—ovarian cancer	0.000218	0.00238	CbGeAlD
Cladribine—ABCG2—endometrium—ovarian cancer	0.000207	0.00226	CbGeAlD
Cladribine—ABCG2—uterus—ovarian cancer	0.000191	0.00208	CbGeAlD
Cladribine—PNP—Daunorubicin—Epirubicin—ovarian cancer	0.000191	0.0631	CbGdCrCtD
Cladribine—DCK—lymph node—ovarian cancer	0.00018	0.00196	CbGeAlD
Cladribine—PNP—Daunorubicin—Doxorubicin—ovarian cancer	0.000177	0.0583	CbGdCrCtD
Cladribine—ABCG2—bone marrow—ovarian cancer	0.000162	0.00177	CbGeAlD
Cladribine—ABCG2—female gonad—ovarian cancer	0.000156	0.0017	CbGeAlD
Cladribine—ABCG2—vagina—ovarian cancer	0.000155	0.00169	CbGeAlD
Cladribine—ABCG2—testis—ovarian cancer	0.000138	0.00151	CbGeAlD
Cladribine—DCK—Doxorubicin—Epirubicin—ovarian cancer	0.000111	0.0368	CbGdCrCtD
Cladribine—DCK—Epirubicin—Doxorubicin—ovarian cancer	0.000103	0.0341	CbGdCrCtD
Cladribine—ABCG2—lymph node—ovarian cancer	0.0001	0.00109	CbGeAlD
Cladribine—Erythema—Docetaxel—ovarian cancer	6.89e-05	0.000485	CcSEcCtD
Cladribine—Malnutrition—Docetaxel—ovarian cancer	6.89e-05	0.000485	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	6.87e-05	0.000484	CcSEcCtD
Cladribine—Nausea—Topotecan—ovarian cancer	6.85e-05	0.000482	CcSEcCtD
Cladribine—Discomfort—Paclitaxel—ovarian cancer	6.84e-05	0.000481	CcSEcCtD
Cladribine—Muscular weakness—Epirubicin—ovarian cancer	6.8e-05	0.000479	CcSEcCtD
Cladribine—Diarrhoea—Vinorelbine—ovarian cancer	6.75e-05	0.000475	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—ovarian cancer	6.71e-05	0.000473	CcSEcCtD
Cladribine—Nausea—Melphalan—ovarian cancer	6.7e-05	0.000472	CcSEcCtD
Cladribine—Confusional state—Paclitaxel—ovarian cancer	6.69e-05	0.000471	CcSEcCtD
Cladribine—Back pain—Docetaxel—ovarian cancer	6.66e-05	0.000469	CcSEcCtD
Cladribine—Oedema—Paclitaxel—ovarian cancer	6.63e-05	0.000467	CcSEcCtD
Cladribine—Eosinophilia—Epirubicin—ovarian cancer	6.6e-05	0.000465	CcSEcCtD
Cladribine—Infection—Paclitaxel—ovarian cancer	6.59e-05	0.000464	CcSEcCtD
Cladribine—Dizziness—Vinorelbine—ovarian cancer	6.52e-05	0.000459	CcSEcCtD
Cladribine—Nervous system disorder—Paclitaxel—ovarian cancer	6.5e-05	0.000458	CcSEcCtD
Cladribine—Thrombocytopenia—Paclitaxel—ovarian cancer	6.49e-05	0.000457	CcSEcCtD
Cladribine—Tachycardia—Paclitaxel—ovarian cancer	6.47e-05	0.000456	CcSEcCtD
Cladribine—Skin disorder—Paclitaxel—ovarian cancer	6.44e-05	0.000454	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	6.43e-05	0.000453	CcSEcCtD
Cladribine—Hyperhidrosis—Paclitaxel—ovarian cancer	6.41e-05	0.000451	CcSEcCtD
Cladribine—Anaemia—Docetaxel—ovarian cancer	6.37e-05	0.000448	CcSEcCtD
Cladribine—Pancytopenia—Epirubicin—ovarian cancer	6.33e-05	0.000446	CcSEcCtD
Cladribine—Anorexia—Paclitaxel—ovarian cancer	6.32e-05	0.000445	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—ovarian cancer	6.3e-05	0.000443	CcSEcCtD
Cladribine—Vomiting—Vinorelbine—ovarian cancer	6.27e-05	0.000441	CcSEcCtD
Cladribine—Neutropenia—Epirubicin—ovarian cancer	6.23e-05	0.000439	CcSEcCtD
Cladribine—Rash—Vinorelbine—ovarian cancer	6.22e-05	0.000438	CcSEcCtD
Cladribine—Dermatitis—Vinorelbine—ovarian cancer	6.21e-05	0.000437	CcSEcCtD
Cladribine—Hypotension—Paclitaxel—ovarian cancer	6.2e-05	0.000436	CcSEcCtD
Cladribine—Upper respiratory tract infection—Epirubicin—ovarian cancer	6.2e-05	0.000436	CcSEcCtD
Cladribine—Headache—Vinorelbine—ovarian cancer	6.18e-05	0.000435	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—ovarian cancer	6.11e-05	0.00043	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	6.04e-05	0.000425	CcSEcCtD
Cladribine—Cough—Docetaxel—ovarian cancer	6.01e-05	0.000423	CcSEcCtD
Cladribine—Insomnia—Paclitaxel—ovarian cancer	6e-05	0.000422	CcSEcCtD
Cladribine—Pneumonia—Epirubicin—ovarian cancer	5.98e-05	0.000421	CcSEcCtD
Cladribine—Paraesthesia—Paclitaxel—ovarian cancer	5.96e-05	0.000419	CcSEcCtD
Cladribine—Infestation NOS—Epirubicin—ovarian cancer	5.94e-05	0.000419	CcSEcCtD
Cladribine—Infestation—Epirubicin—ovarian cancer	5.94e-05	0.000419	CcSEcCtD
Cladribine—Dyspnoea—Paclitaxel—ovarian cancer	5.91e-05	0.000416	CcSEcCtD
Cladribine—Somnolence—Paclitaxel—ovarian cancer	5.9e-05	0.000415	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	5.89e-05	0.000415	CcSEcCtD
Cladribine—Chest pain—Docetaxel—ovarian cancer	5.86e-05	0.000413	CcSEcCtD
Cladribine—Arthralgia—Docetaxel—ovarian cancer	5.86e-05	0.000413	CcSEcCtD
Cladribine—Myalgia—Docetaxel—ovarian cancer	5.86e-05	0.000413	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—ovarian cancer	5.86e-05	0.000413	CcSEcCtD
Cladribine—Nausea—Vinorelbine—ovarian cancer	5.86e-05	0.000412	CcSEcCtD
Cladribine—Renal failure—Epirubicin—ovarian cancer	5.84e-05	0.000411	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	5.82e-05	0.00041	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—ovarian cancer	5.78e-05	0.000407	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—ovarian cancer	5.78e-05	0.000407	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—ovarian cancer	5.77e-05	0.000406	CcSEcCtD
Cladribine—Decreased appetite—Paclitaxel—ovarian cancer	5.77e-05	0.000406	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	5.73e-05	0.000404	CcSEcCtD
Cladribine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	5.73e-05	0.000403	CcSEcCtD
Cladribine—Fatigue—Paclitaxel—ovarian cancer	5.72e-05	0.000403	CcSEcCtD
Cladribine—Pain—Paclitaxel—ovarian cancer	5.67e-05	0.000399	CcSEcCtD
Cladribine—Constipation—Paclitaxel—ovarian cancer	5.67e-05	0.000399	CcSEcCtD
Cladribine—Confusional state—Docetaxel—ovarian cancer	5.67e-05	0.000399	CcSEcCtD
Cladribine—Hepatobiliary disease—Epirubicin—ovarian cancer	5.62e-05	0.000396	CcSEcCtD
Cladribine—Oedema—Docetaxel—ovarian cancer	5.62e-05	0.000396	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—ovarian cancer	5.61e-05	0.000395	CcSEcCtD
Cladribine—Infection—Docetaxel—ovarian cancer	5.58e-05	0.000393	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—ovarian cancer	5.53e-05	0.00039	CcSEcCtD
Cladribine—Nervous system disorder—Docetaxel—ovarian cancer	5.51e-05	0.000388	CcSEcCtD
Cladribine—Thrombocytopenia—Docetaxel—ovarian cancer	5.5e-05	0.000388	CcSEcCtD
Cladribine—Infestation—Doxorubicin—ovarian cancer	5.5e-05	0.000387	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—ovarian cancer	5.5e-05	0.000387	CcSEcCtD
Cladribine—Tachycardia—Docetaxel—ovarian cancer	5.49e-05	0.000386	CcSEcCtD
Cladribine—Feeling abnormal—Paclitaxel—ovarian cancer	5.47e-05	0.000385	CcSEcCtD
Cladribine—Skin disorder—Docetaxel—ovarian cancer	5.46e-05	0.000384	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	5.45e-05	0.000384	CcSEcCtD
Cladribine—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.42e-05	0.000382	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—ovarian cancer	5.41e-05	0.000381	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—ovarian cancer	5.36e-05	0.000378	CcSEcCtD
Cladribine—Anorexia—Docetaxel—ovarian cancer	5.36e-05	0.000377	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—ovarian cancer	5.35e-05	0.000376	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—ovarian cancer	5.35e-05	0.000376	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—ovarian cancer	5.34e-05	0.000376	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—ovarian cancer	5.3e-05	0.000373	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—ovarian cancer	5.27e-05	0.000371	CcSEcCtD
Cladribine—Urticaria—Paclitaxel—ovarian cancer	5.27e-05	0.000371	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—ovarian cancer	5.26e-05	0.00037	CcSEcCtD
Cladribine—Hypotension—Docetaxel—ovarian cancer	5.25e-05	0.00037	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—ovarian cancer	5.24e-05	0.000369	CcSEcCtD
Cladribine—Body temperature increased—Paclitaxel—ovarian cancer	5.24e-05	0.000369	CcSEcCtD
Cladribine—Abdominal pain—Paclitaxel—ovarian cancer	5.24e-05	0.000369	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—ovarian cancer	5.23e-05	0.000368	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.2e-05	0.000366	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—ovarian cancer	5.19e-05	0.000365	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.12e-05	0.000361	CcSEcCtD
Cladribine—Insomnia—Docetaxel—ovarian cancer	5.08e-05	0.000358	CcSEcCtD
Cladribine—Paraesthesia—Docetaxel—ovarian cancer	5.05e-05	0.000355	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—ovarian cancer	5.05e-05	0.000355	CcSEcCtD
Cladribine—Dyspnoea—Docetaxel—ovarian cancer	5.01e-05	0.000353	CcSEcCtD
Cladribine—Somnolence—Docetaxel—ovarian cancer	5e-05	0.000352	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—ovarian cancer	4.99e-05	0.000351	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—ovarian cancer	4.96e-05	0.000349	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—ovarian cancer	4.95e-05	0.000349	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—ovarian cancer	4.94e-05	0.000348	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—ovarian cancer	4.9e-05	0.000345	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—ovarian cancer	4.89e-05	0.000344	CcSEcCtD
Cladribine—Hypersensitivity—Paclitaxel—ovarian cancer	4.89e-05	0.000344	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—ovarian cancer	4.88e-05	0.000343	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—ovarian cancer	4.86e-05	0.000343	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—ovarian cancer	4.85e-05	0.000342	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—ovarian cancer	4.85e-05	0.000342	CcSEcCtD
Cladribine—Fatigue—Docetaxel—ovarian cancer	4.85e-05	0.000341	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—ovarian cancer	4.84e-05	0.000341	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—ovarian cancer	4.84e-05	0.000341	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—ovarian cancer	4.82e-05	0.000339	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—ovarian cancer	4.81e-05	0.000339	CcSEcCtD
Cladribine—Constipation—Docetaxel—ovarian cancer	4.81e-05	0.000338	CcSEcCtD
Cladribine—Pain—Docetaxel—ovarian cancer	4.81e-05	0.000338	CcSEcCtD
Cladribine—Chills—Epirubicin—ovarian cancer	4.79e-05	0.000337	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—ovarian cancer	4.77e-05	0.000336	CcSEcCtD
Cladribine—Asthenia—Paclitaxel—ovarian cancer	4.76e-05	0.000335	CcSEcCtD
Cladribine—Alopecia—Epirubicin—ovarian cancer	4.72e-05	0.000332	CcSEcCtD
Cladribine—Pruritus—Paclitaxel—ovarian cancer	4.69e-05	0.00033	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—ovarian cancer	4.68e-05	0.000329	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—ovarian cancer	4.67e-05	0.000329	CcSEcCtD
Cladribine—Erythema—Epirubicin—ovarian cancer	4.65e-05	0.000327	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—ovarian cancer	4.65e-05	0.000327	CcSEcCtD
Cladribine—Feeling abnormal—Docetaxel—ovarian cancer	4.63e-05	0.000326	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—ovarian cancer	4.61e-05	0.000325	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—ovarian cancer	4.6e-05	0.000324	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—ovarian cancer	4.58e-05	0.000323	CcSEcCtD
Cladribine—Flatulence—Epirubicin—ovarian cancer	4.58e-05	0.000322	CcSEcCtD
Cladribine—Diarrhoea—Paclitaxel—ovarian cancer	4.54e-05	0.00032	CcSEcCtD
Cladribine—Back pain—Epirubicin—ovarian cancer	4.49e-05	0.000316	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—ovarian cancer	4.48e-05	0.000315	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—ovarian cancer	4.46e-05	0.000314	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—ovarian cancer	4.45e-05	0.000313	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—ovarian cancer	4.44e-05	0.000313	CcSEcCtD
Cladribine—Body temperature increased—Docetaxel—ovarian cancer	4.44e-05	0.000313	CcSEcCtD
Cladribine—Chills—Doxorubicin—ovarian cancer	4.43e-05	0.000312	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—ovarian cancer	4.41e-05	0.000311	CcSEcCtD
Cladribine—Dizziness—Paclitaxel—ovarian cancer	4.39e-05	0.000309	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—ovarian cancer	4.36e-05	0.000307	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—ovarian cancer	4.33e-05	0.000305	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—ovarian cancer	4.31e-05	0.000304	CcSEcCtD
Cladribine—Erythema—Doxorubicin—ovarian cancer	4.3e-05	0.000303	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—ovarian cancer	4.3e-05	0.000303	CcSEcCtD
Cladribine—Anaemia—Epirubicin—ovarian cancer	4.29e-05	0.000302	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—ovarian cancer	4.24e-05	0.000298	CcSEcCtD
Cladribine—Vomiting—Paclitaxel—ovarian cancer	4.22e-05	0.000297	CcSEcCtD
Cladribine—Malaise—Epirubicin—ovarian cancer	4.19e-05	0.000295	CcSEcCtD
Cladribine—Rash—Paclitaxel—ovarian cancer	4.18e-05	0.000294	CcSEcCtD
Cladribine—Dermatitis—Paclitaxel—ovarian cancer	4.18e-05	0.000294	CcSEcCtD
Cladribine—Back pain—Doxorubicin—ovarian cancer	4.16e-05	0.000293	CcSEcCtD
Cladribine—Headache—Paclitaxel—ovarian cancer	4.15e-05	0.000293	CcSEcCtD
Cladribine—Hypersensitivity—Docetaxel—ovarian cancer	4.14e-05	0.000292	CcSEcCtD
Cladribine—Cough—Epirubicin—ovarian cancer	4.05e-05	0.000285	CcSEcCtD
Cladribine—Asthenia—Docetaxel—ovarian cancer	4.03e-05	0.000284	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—ovarian cancer	3.99e-05	0.000281	CcSEcCtD
Cladribine—Pruritus—Docetaxel—ovarian cancer	3.98e-05	0.00028	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—ovarian cancer	3.97e-05	0.00028	CcSEcCtD
Cladribine—Myalgia—Epirubicin—ovarian cancer	3.96e-05	0.000278	CcSEcCtD
Cladribine—Chest pain—Epirubicin—ovarian cancer	3.96e-05	0.000278	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—ovarian cancer	3.96e-05	0.000278	CcSEcCtD
Cladribine—Anxiety—Epirubicin—ovarian cancer	3.94e-05	0.000278	CcSEcCtD
Cladribine—Nausea—Paclitaxel—ovarian cancer	3.94e-05	0.000277	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.93e-05	0.000277	CcSEcCtD
Cladribine—Discomfort—Epirubicin—ovarian cancer	3.91e-05	0.000275	CcSEcCtD
Cladribine—Malaise—Doxorubicin—ovarian cancer	3.88e-05	0.000273	CcSEcCtD
Cladribine—Diarrhoea—Docetaxel—ovarian cancer	3.85e-05	0.000271	CcSEcCtD
Cladribine—Confusional state—Epirubicin—ovarian cancer	3.82e-05	0.000269	CcSEcCtD
Cladribine—Oedema—Epirubicin—ovarian cancer	3.79e-05	0.000267	CcSEcCtD
Cladribine—Infection—Epirubicin—ovarian cancer	3.77e-05	0.000265	CcSEcCtD
Cladribine—Cough—Doxorubicin—ovarian cancer	3.75e-05	0.000264	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—ovarian cancer	3.72e-05	0.000262	CcSEcCtD
Cladribine—Dizziness—Docetaxel—ovarian cancer	3.72e-05	0.000262	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—ovarian cancer	3.71e-05	0.000261	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—ovarian cancer	3.7e-05	0.000261	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—ovarian cancer	3.68e-05	0.000259	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—ovarian cancer	3.67e-05	0.000258	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—ovarian cancer	3.66e-05	0.000258	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—ovarian cancer	3.66e-05	0.000258	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—ovarian cancer	3.66e-05	0.000258	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—ovarian cancer	3.65e-05	0.000257	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.63e-05	0.000256	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—ovarian cancer	3.62e-05	0.000255	CcSEcCtD
Cladribine—Anorexia—Epirubicin—ovarian cancer	3.61e-05	0.000254	CcSEcCtD
Cladribine—Vomiting—Docetaxel—ovarian cancer	3.57e-05	0.000252	CcSEcCtD
Cladribine—Rash—Docetaxel—ovarian cancer	3.54e-05	0.00025	CcSEcCtD
Cladribine—Hypotension—Epirubicin—ovarian cancer	3.54e-05	0.000249	CcSEcCtD
Cladribine—Dermatitis—Docetaxel—ovarian cancer	3.54e-05	0.000249	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—ovarian cancer	3.54e-05	0.000249	CcSEcCtD
Cladribine—Headache—Docetaxel—ovarian cancer	3.52e-05	0.000248	CcSEcCtD
Cladribine—Oedema—Doxorubicin—ovarian cancer	3.51e-05	0.000247	CcSEcCtD
Cladribine—Infection—Doxorubicin—ovarian cancer	3.49e-05	0.000245	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.45e-05	0.000243	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—ovarian cancer	3.44e-05	0.000242	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—ovarian cancer	3.43e-05	0.000242	CcSEcCtD
Cladribine—Insomnia—Epirubicin—ovarian cancer	3.43e-05	0.000241	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—ovarian cancer	3.42e-05	0.000241	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—ovarian cancer	3.41e-05	0.00024	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—ovarian cancer	3.4e-05	0.00024	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—ovarian cancer	3.39e-05	0.000239	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—ovarian cancer	3.38e-05	0.000238	CcSEcCtD
Cladribine—Somnolence—Epirubicin—ovarian cancer	3.37e-05	0.000237	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—ovarian cancer	3.34e-05	0.000235	CcSEcCtD
Cladribine—Nausea—Docetaxel—ovarian cancer	3.34e-05	0.000235	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—ovarian cancer	3.3e-05	0.000232	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—ovarian cancer	3.28e-05	0.000231	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.27e-05	0.00023	CcSEcCtD
Cladribine—Fatigue—Epirubicin—ovarian cancer	3.27e-05	0.00023	CcSEcCtD
Cladribine—Pain—Epirubicin—ovarian cancer	3.24e-05	0.000228	CcSEcCtD
Cladribine—Constipation—Epirubicin—ovarian cancer	3.24e-05	0.000228	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.2e-05	0.000225	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—ovarian cancer	3.17e-05	0.000223	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—ovarian cancer	3.15e-05	0.000222	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—ovarian cancer	3.13e-05	0.00022	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—ovarian cancer	3.12e-05	0.00022	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—ovarian cancer	3.12e-05	0.00022	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—ovarian cancer	3.1e-05	0.000218	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—ovarian cancer	3.05e-05	0.000215	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.03e-05	0.000213	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—ovarian cancer	3.02e-05	0.000213	CcSEcCtD
Cladribine—POLA1—S Phase—MYC—ovarian cancer	3.02e-05	0.000293	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—AQP3—ovarian cancer	3.01e-05	0.000292	CbGpPWpGaD
Cladribine—Urticaria—Epirubicin—ovarian cancer	3.01e-05	0.000212	CcSEcCtD
Cladribine—Pain—Doxorubicin—ovarian cancer	3e-05	0.000211	CcSEcCtD
Cladribine—Constipation—Doxorubicin—ovarian cancer	3e-05	0.000211	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—ovarian cancer	3e-05	0.000211	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—ovarian cancer	3e-05	0.000211	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3e-05	0.00029	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—BIRC5—ovarian cancer	2.99e-05	0.00029	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	2.98e-05	0.000289	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	2.97e-05	0.000288	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND2—ovarian cancer	2.96e-05	0.000287	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	2.95e-05	0.000286	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—MAPK1—ovarian cancer	2.93e-05	0.000284	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	2.92e-05	0.000283	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TERT—ovarian cancer	2.9e-05	0.000281	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—ovarian cancer	2.89e-05	0.000204	CcSEcCtD
Cladribine—RRM1—Metabolism—YAP1—ovarian cancer	2.89e-05	0.00028	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.89e-05	0.00028	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—BIRC5—ovarian cancer	2.87e-05	0.000278	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.87e-05	0.000202	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	2.87e-05	0.000278	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.86e-05	0.000277	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CHEK2—ovarian cancer	2.82e-05	0.000274	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CTNNB1—ovarian cancer	2.81e-05	0.000273	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CAV1—ovarian cancer	2.81e-05	0.000272	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—ovarian cancer	2.8e-05	0.000272	CbGpPWpGaD
Cladribine—Hypersensitivity—Epirubicin—ovarian cancer	2.79e-05	0.000197	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—ovarian cancer	2.79e-05	0.00027	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	2.79e-05	0.00027	CbGpPWpGaD
Cladribine—Urticaria—Doxorubicin—ovarian cancer	2.79e-05	0.000196	CcSEcCtD
Cladribine—POLE—Cell Cycle—TERT—ovarian cancer	2.78e-05	0.00027	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AQP3—ovarian cancer	2.78e-05	0.000269	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.77e-05	0.000269	CbGpPWpGaD
Cladribine—Abdominal pain—Doxorubicin—ovarian cancer	2.77e-05	0.000195	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—ovarian cancer	2.77e-05	0.000195	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	2.77e-05	0.000268	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP9—ovarian cancer	2.76e-05	0.000267	CbGpPWpGaD
Cladribine—Asthenia—Epirubicin—ovarian cancer	2.72e-05	0.000192	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.72e-05	0.000263	CbGpPWpGaD
Cladribine—Pruritus—Epirubicin—ovarian cancer	2.68e-05	0.000189	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	2.67e-05	0.000259	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.66e-05	0.000258	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.65e-05	0.000256	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—BRCA1—ovarian cancer	2.64e-05	0.000256	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND2—ovarian cancer	2.64e-05	0.000256	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.62e-05	0.000254	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDKN1B—ovarian cancer	2.61e-05	0.000253	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.61e-05	0.000253	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—ovarian cancer	2.59e-05	0.000183	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—CCNE1—ovarian cancer	2.59e-05	0.000251	CbGpPWpGaD
Cladribine—Hypersensitivity—Doxorubicin—ovarian cancer	2.58e-05	0.000182	CcSEcCtD
Cladribine—RRM2B—Metabolism—PIK3CG—ovarian cancer	2.56e-05	0.000248	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.55e-05	0.000248	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TYMS—ovarian cancer	2.54e-05	0.000247	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—ovarian cancer	2.52e-05	0.000177	CcSEcCtD
Cladribine—Dizziness—Epirubicin—ovarian cancer	2.51e-05	0.000177	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCND1—ovarian cancer	2.49e-05	0.000242	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—PPP2R1A—ovarian cancer	2.49e-05	0.000242	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—ovarian cancer	2.48e-05	0.000175	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—VEGFA—ovarian cancer	2.48e-05	0.00024	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—ovarian cancer	2.45e-05	0.000238	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—NRAS—ovarian cancer	2.45e-05	0.000237	CbGpPWpGaD
Cladribine—PNP—Metabolism—CAV1—ovarian cancer	2.43e-05	0.000236	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—ovarian cancer	2.42e-05	0.000235	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—ovarian cancer	2.41e-05	0.00017	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—ovarian cancer	2.4e-05	0.000169	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BRCA2—ovarian cancer	2.39e-05	0.000232	CbGpPWpGaD
Cladribine—Rash—Epirubicin—ovarian cancer	2.39e-05	0.000168	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—ovarian cancer	2.39e-05	0.000168	CcSEcCtD
Cladribine—RRM2—Metabolism—YAP1—ovarian cancer	2.38e-05	0.000231	CbGpPWpGaD
Cladribine—Headache—Epirubicin—ovarian cancer	2.38e-05	0.000167	CcSEcCtD
Cladribine—RRM1—Metabolism—FASN—ovarian cancer	2.36e-05	0.000228	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NME2—ovarian cancer	2.36e-05	0.000228	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK3—ovarian cancer	2.34e-05	0.000227	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NME2—ovarian cancer	2.33e-05	0.000226	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—ovarian cancer	2.32e-05	0.000163	CcSEcCtD
Cladribine—RRM1—Metabolism—SLC5A5—ovarian cancer	2.32e-05	0.000225	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCNE1—ovarian cancer	2.32e-05	0.000224	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.31e-05	0.000224	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK3—ovarian cancer	2.3e-05	0.000223	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—BIRC5—ovarian cancer	2.29e-05	0.000222	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	2.28e-05	0.000221	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TYMS—ovarian cancer	2.27e-05	0.00022	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	2.26e-05	0.000219	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—ovarian cancer	2.25e-05	0.000159	CcSEcCtD
Cladribine—RRM2B—Metabolism—PIK3CD—ovarian cancer	2.25e-05	0.000218	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ESR1—ovarian cancer	2.24e-05	0.000217	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SLC2A1—ovarian cancer	2.24e-05	0.000217	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—ovarian cancer	2.24e-05	0.000217	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—ovarian cancer	2.23e-05	0.000157	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—MAPK1—ovarian cancer	2.23e-05	0.000216	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—ovarian cancer	2.23e-05	0.000216	CbGpPWpGaD
Cladribine—DCK—Metabolism—YAP1—ovarian cancer	2.22e-05	0.000216	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CG—ovarian cancer	2.22e-05	0.000215	CbGpPWpGaD
Cladribine—Rash—Doxorubicin—ovarian cancer	2.21e-05	0.000156	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—ovarian cancer	2.21e-05	0.000156	CcSEcCtD
Cladribine—Headache—Doxorubicin—ovarian cancer	2.2e-05	0.000155	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.19e-05	0.000212	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.18e-05	0.000211	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NME2—ovarian cancer	2.17e-05	0.000211	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP1B1—ovarian cancer	2.15e-05	0.000208	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.12e-05	0.000206	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—ovarian cancer	2.11e-05	0.000204	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	2.11e-05	0.000204	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—ovarian cancer	2.08e-05	0.000147	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.08e-05	0.000201	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.08e-05	0.000201	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK3—ovarian cancer	2.06e-05	0.000199	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—BIRC5—ovarian cancer	2.05e-05	0.000198	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—ovarian cancer	2e-05	0.000194	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK3—ovarian cancer	1.98e-05	0.000192	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TERT—ovarian cancer	1.98e-05	0.000192	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	1.96e-05	0.00019	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.96e-05	0.00019	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CB—ovarian cancer	1.96e-05	0.00019	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK1—ovarian cancer	1.96e-05	0.00019	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CD—ovarian cancer	1.95e-05	0.000189	CbGpPWpGaD
Cladribine—RRM2—Metabolism—FASN—ovarian cancer	1.94e-05	0.000188	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC5A5—ovarian cancer	1.91e-05	0.000185	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPP2R1A—ovarian cancer	1.9e-05	0.000184	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK1—ovarian cancer	1.89e-05	0.000183	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	1.88e-05	0.000183	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	1.88e-05	0.000182	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—ovarian cancer	1.87e-05	0.000182	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC2A1—ovarian cancer	1.84e-05	0.000179	CbGpPWpGaD
Cladribine—DCK—Metabolism—FASN—ovarian cancer	1.81e-05	0.000176	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.8e-05	0.000175	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—ovarian cancer	1.8e-05	0.000174	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—ovarian cancer	1.79e-05	0.000174	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC5A5—ovarian cancer	1.78e-05	0.000173	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ABCB1—ovarian cancer	1.77e-05	0.000171	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP1B1—ovarian cancer	1.77e-05	0.000171	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN1B—ovarian cancer	1.76e-05	0.00017	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.74e-05	0.000169	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TYMS—ovarian cancer	1.74e-05	0.000168	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC2A1—ovarian cancer	1.72e-05	0.000167	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—IL6—ovarian cancer	1.71e-05	0.000166	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CB—ovarian cancer	1.7e-05	0.000165	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTEN—ovarian cancer	1.69e-05	0.000164	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN1B—ovarian cancer	1.69e-05	0.000163	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—ovarian cancer	1.67e-05	0.000162	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP1B1—ovarian cancer	1.65e-05	0.00016	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—ovarian cancer	1.64e-05	0.000159	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—ovarian cancer	1.61e-05	0.000156	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—AKT1—ovarian cancer	1.58e-05	0.000153	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPP2R1A—ovarian cancer	1.57e-05	0.000152	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK3—ovarian cancer	1.54e-05	0.00015	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.52e-05	0.000148	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYTB—ovarian cancer	1.52e-05	0.000147	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.51e-05	0.000146	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYTB—ovarian cancer	1.5e-05	0.000146	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—ovarian cancer	1.5e-05	0.000146	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK3—ovarian cancer	1.48e-05	0.000144	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.47e-05	0.000143	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.47e-05	0.000143	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK1—ovarian cancer	1.47e-05	0.000142	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—ovarian cancer	1.47e-05	0.000142	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPP2R1A—ovarian cancer	1.46e-05	0.000142	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.46e-05	0.000141	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—ovarian cancer	1.45e-05	0.000141	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—ovarian cancer	1.44e-05	0.00014	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—ovarian cancer	1.43e-05	0.000138	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK3—ovarian cancer	1.41e-05	0.000137	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK1—ovarian cancer	1.41e-05	0.000137	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.41e-05	0.000136	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYTB—ovarian cancer	1.4e-05	0.000136	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CAV1—ovarian cancer	1.4e-05	0.000136	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK3—ovarian cancer	1.38e-05	0.000134	CbGpPWpGaD
Cladribine—DCK—Metabolism—ABCB1—ovarian cancer	1.36e-05	0.000132	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.36e-05	0.000132	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK1—ovarian cancer	1.34e-05	0.00013	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—ovarian cancer	1.34e-05	0.00013	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	1.34e-05	0.00013	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—ovarian cancer	1.34e-05	0.000129	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPP1CC—ovarian cancer	1.33e-05	0.000129	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BRIP1—ovarian cancer	1.33e-05	0.000129	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK3—ovarian cancer	1.33e-05	0.000128	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK1—ovarian cancer	1.31e-05	0.000127	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BRIP1—ovarian cancer	1.31e-05	0.000127	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPP1CC—ovarian cancer	1.31e-05	0.000127	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—ovarian cancer	1.29e-05	0.000125	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—ovarian cancer	1.28e-05	0.000124	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CG—ovarian cancer	1.27e-05	0.000123	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK1—ovarian cancer	1.26e-05	0.000122	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPP1CC—ovarian cancer	1.22e-05	0.000119	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BRIP1—ovarian cancer	1.22e-05	0.000119	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1B—ovarian cancer	1.2e-05	0.000116	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MAPK3—ovarian cancer	1.2e-05	0.000116	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—ovarian cancer	1.19e-05	0.000116	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—ovarian cancer	1.17e-05	0.000113	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.16e-05	0.000113	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CAV1—ovarian cancer	1.15e-05	0.000112	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.15e-05	0.000111	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—ovarian cancer	1.15e-05	0.000111	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CD—ovarian cancer	1.12e-05	0.000109	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—ovarian cancer	1.1e-05	0.000107	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	1.08e-05	0.000105	CbGpPWpGaD
Cladribine—DCK—Metabolism—CAV1—ovarian cancer	1.08e-05	0.000104	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.07e-05	0.000104	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—ovarian cancer	1.06e-05	0.000103	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK3—ovarian cancer	1.06e-05	0.000102	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CG—ovarian cancer	1.05e-05	0.000102	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—ovarian cancer	1.04e-05	0.0001	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—ovarian cancer	1.03e-05	9.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	1.01e-05	9.78e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK1—ovarian cancer	1.01e-05	9.74e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CG—ovarian cancer	9.8e-06	9.5e-05	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—ovarian cancer	9.76e-06	9.46e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CB—ovarian cancer	9.76e-06	9.46e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK3—ovarian cancer	9.45e-06	9.15e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CD—ovarian cancer	9.22e-06	8.94e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—ovarian cancer	9.19e-06	8.9e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK1—ovarian cancer	8.99e-06	8.71e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—YAP1—ovarian cancer	8.9e-06	8.62e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—YAP1—ovarian cancer	8.81e-06	8.54e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.69e-06	8.43e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CD—ovarian cancer	8.62e-06	8.35e-05	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—ovarian cancer	8.46e-06	8.2e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—ovarian cancer	8.43e-06	8.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MAPK1—ovarian cancer	8.3e-06	8.04e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—YAP1—ovarian cancer	8.21e-06	7.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.1e-06	7.85e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—ovarian cancer	8.09e-06	7.84e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CB—ovarian cancer	8.04e-06	7.79e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MAPK1—ovarian cancer	7.73e-06	7.49e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—ovarian cancer	7.54e-06	7.31e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CB—ovarian cancer	7.51e-06	7.28e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—FASN—ovarian cancer	7.25e-06	7.03e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—FASN—ovarian cancer	7.18e-06	6.96e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC5A5—ovarian cancer	7.14e-06	6.92e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC5A5—ovarian cancer	7.06e-06	6.84e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—ovarian cancer	6.94e-06	6.73e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A1—ovarian cancer	6.89e-06	6.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A1—ovarian cancer	6.82e-06	6.61e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—FASN—ovarian cancer	6.69e-06	6.49e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—ovarian cancer	6.66e-06	6.46e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1B1—ovarian cancer	6.61e-06	6.4e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC5A5—ovarian cancer	6.58e-06	6.38e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1B1—ovarian cancer	6.54e-06	6.34e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—ovarian cancer	6.49e-06	6.29e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A1—ovarian cancer	6.36e-06	6.16e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—ovarian cancer	6.21e-06	6.02e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1B1—ovarian cancer	6.09e-06	5.91e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—ovarian cancer	5.95e-06	5.77e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPP2R1A—ovarian cancer	5.86e-06	5.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	5.8e-06	5.62e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—ovarian cancer	5.44e-06	5.27e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	5.41e-06	5.24e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—ovarian cancer	5.38e-06	5.22e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—ovarian cancer	5.34e-06	5.18e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—ovarian cancer	5.29e-06	5.13e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—ovarian cancer	5.02e-06	4.86e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—ovarian cancer	4.93e-06	4.78e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—ovarian cancer	4.9e-06	4.75e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—ovarian cancer	4.86e-06	4.71e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—ovarian cancer	4.58e-06	4.44e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CAV1—ovarian cancer	4.31e-06	4.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CAV1—ovarian cancer	4.26e-06	4.13e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—ovarian cancer	4e-06	3.88e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CAV1—ovarian cancer	3.97e-06	3.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CG—ovarian cancer	3.92e-06	3.8e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CG—ovarian cancer	3.88e-06	3.76e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—ovarian cancer	3.74e-06	3.62e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CG—ovarian cancer	3.62e-06	3.51e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CD—ovarian cancer	3.45e-06	3.34e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CD—ovarian cancer	3.41e-06	3.31e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CD—ovarian cancer	3.18e-06	3.08e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CB—ovarian cancer	3.01e-06	2.91e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CB—ovarian cancer	2.97e-06	2.88e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CB—ovarian cancer	2.77e-06	2.69e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—ovarian cancer	2.6e-06	2.52e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—ovarian cancer	2.57e-06	2.49e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—ovarian cancer	2.4e-06	2.32e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.83e-06	1.78e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	1.81e-06	1.76e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	1.69e-06	1.64e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—ovarian cancer	1.5e-06	1.45e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—ovarian cancer	1.48e-06	1.44e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—ovarian cancer	1.38e-06	1.34e-05	CbGpPWpGaD
